Reported Earnings • May 17
Full year 2026 earnings released: JP¥4.62 loss per share (vs JP¥65.47 loss in FY 2025) Full year 2026 results: JP¥4.62 loss per share (improved from JP¥65.47 loss in FY 2025). Revenue: JP¥13.2b (up 1.3% from FY 2025). Net loss: JP¥77.0m (loss narrowed 93% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Aankondiging • May 13
Transgenic Group Inc., Annual General Meeting, Jun 18, 2026 Transgenic Group Inc., Annual General Meeting, Jun 18, 2026. Reported Earnings • Feb 11
Third quarter 2026 earnings released: JP¥0.06 loss per share (vs JP¥6.55 loss in 3Q 2025) Third quarter 2026 results: JP¥0.06 loss per share (improved from JP¥6.55 loss in 3Q 2025). Revenue: JP¥3.47b (flat on 3Q 2025). Net loss: JP¥1.00m (loss narrowed 99% from 3Q 2025). Profit margin: 0% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Aankondiging • Dec 18
Transgenic Group Inc. to Report Q3, 2026 Results on Feb 10, 2026 Transgenic Group Inc. announced that they will report Q3, 2026 results on Feb 10, 2026 Reported Earnings • Nov 15
Second quarter 2026 earnings released: EPS: JP¥0.18 (vs JP¥4.99 loss in 2Q 2025) Second quarter 2026 results: EPS: JP¥0.18 (up from JP¥4.99 loss in 2Q 2025). Revenue: JP¥3.03b (down 12% from 2Q 2025). Net income: JP¥3.00m (up JP¥86.0m from 2Q 2025). Profit margin: 0.1% (up from net loss in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Aankondiging • Sep 04
Transgenic Group Inc. to Report Q2, 2026 Results on Nov 12, 2025 Transgenic Group Inc. announced that they will report Q2, 2026 results on Nov 12, 2025 Reported Earnings • Aug 14
First quarter 2026 earnings released: EPS: JP¥1.56 (vs JP¥5.97 loss in 1Q 2025) First quarter 2026 results: EPS: JP¥1.56 (up from JP¥5.97 loss in 1Q 2025). Revenue: JP¥3.20b (up 11% from 1Q 2025). Net income: JP¥26.0m (up JP¥125.0m from 1Q 2025). Profit margin: 0.8% (up from net loss in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance. Aankondiging • Jun 26
Transgenic Group Inc. to Report Q1, 2026 Results on Aug 14, 2025 Transgenic Group Inc. announced that they will report Q1, 2026 results on Aug 14, 2025 Reported Earnings • Jun 19
Full year 2025 earnings released: JP¥65.47 loss per share (vs JP¥0.24 profit in FY 2024) Full year 2025 results: JP¥65.47 loss per share (down from JP¥0.24 profit in FY 2024). Revenue: JP¥13.0b (flat on FY 2024). Net loss: JP¥1.09b (down JP¥1.09b from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Aankondiging • Jun 16
Transgenic Group Inc., Annual General Meeting, Jun 30, 2025 Transgenic Group Inc., Annual General Meeting, Jun 30, 2025. New Risk • Apr 07
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥2.73b market cap, or US$18.7m). Aankondiging • Mar 12
Transgenic Group Inc. to Report Fiscal Year 2025 Results on May 13, 2025 Transgenic Group Inc. announced that they will report fiscal year 2025 results on May 13, 2025 Reported Earnings • Feb 17
Third quarter 2025 earnings released: JP¥6.55 loss per share (vs JP¥5.10 loss in 3Q 2024) Third quarter 2025 results: JP¥6.55 loss per share (further deteriorated from JP¥5.10 loss in 3Q 2024). Revenue: JP¥3.50b (up 3.9% from 3Q 2024). Net loss: JP¥109.0m (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. New Risk • Dec 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥3.03b market cap, or US$19.2m). Aankondiging • Dec 04
Transgenic Group Inc. to Report Q3, 2025 Results on Feb 14, 2025 Transgenic Group Inc. announced that they will report Q3, 2025 results on Feb 14, 2025 Reported Earnings • Nov 18
Second quarter 2025 earnings released: JP¥4.99 loss per share (vs JP¥1.78 loss in 2Q 2024) Second quarter 2025 results: JP¥4.99 loss per share (further deteriorated from JP¥1.78 loss in 2Q 2024). Revenue: JP¥3.43b (up 11% from 2Q 2024). Net loss: JP¥83.0m (loss widened 177% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 11
First quarter 2025 earnings released: JP¥5.97 loss per share (vs JP¥4.63 profit in 1Q 2024) First quarter 2025 results: JP¥5.97 loss per share (down from JP¥4.63 profit in 1Q 2024). Revenue: JP¥2.88b (down 12% from 1Q 2024). Net loss: JP¥99.0m (down 227% from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 26
Full year 2024 earnings released: EPS: JP¥0.24 (vs JP¥24.28 loss in FY 2023) Full year 2024 results: EPS: JP¥0.24 (up from JP¥24.28 loss in FY 2023). Revenue: JP¥13.1b (up 14% from FY 2023). Net income: JP¥4.00m (up JP¥413.0m from FY 2023). Profit margin: 0% (up from net loss in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance. Aankondiging • Jun 20
Trans Genic Inc. to Report Q1, 2025 Results on Aug 09, 2024 Trans Genic Inc. announced that they will report Q1, 2025 results on Aug 09, 2024 Reported Earnings • May 13
Full year 2024 earnings released: EPS: JP¥0.24 (vs JP¥24.28 loss in FY 2023) Full year 2024 results: EPS: JP¥0.24 (up from JP¥24.28 loss in FY 2023). Revenue: JP¥13.1b (up 14% from FY 2023). Net income: JP¥4.00m (up JP¥413.0m from FY 2023). Profit margin: 0% (up from net loss in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance. Aankondiging • May 12
Trans Genic Inc., Annual General Meeting, Jun 20, 2024 Trans Genic Inc., Annual General Meeting, Jun 20, 2024. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥3.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 24 June 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.2%). In line with average of industry peers (1.2%). Aankondiging • Mar 06
Trans Genic Inc. to Report Fiscal Year 2024 Results on May 10, 2024 Trans Genic Inc. announced that they will report fiscal year 2024 results on May 10, 2024 Reported Earnings • Feb 11
Third quarter 2024 earnings released: JP¥5.10 loss per share (vs JP¥7.59 profit in 3Q 2023) Third quarter 2024 results: JP¥5.10 loss per share (down from JP¥7.59 profit in 3Q 2023). Revenue: JP¥3.37b (up 15% from 3Q 2023). Net loss: JP¥86.0m (down 167% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings. New Risk • Jan 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (JP¥4.45b market cap, or US$30.2m). Aankondiging • Nov 29
Trans Genic Inc. to Report Q3, 2024 Results on Feb 09, 2024 Trans Genic Inc. announced that they will report Q3, 2024 results on Feb 09, 2024 Aankondiging • Nov 24
Trans Genic Inc. (TSE:2342) announces an Equity Buyback for 300,000 shares, representing 1.78% for ¥100 million. Trans Genic Inc. (TSE:2342) announces a share repurchase program. Under the program, the company will repurchase up to 300,000 shares, representing 1.78% of its issued share capital, for ¥100 million. The purpose of the program is agile capital policy implementation and shareholder return measures in response to changes in the business environment. The program is valid till March 22, 2024. As of November 22, 2023, the company had 16,893,719 shares issued (excluding treasury stock) and 105,422 shares in treasury. Reported Earnings • Nov 12
Second quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥4.69 profit in 2Q 2023) Second quarter 2024 results: JP¥1.78 loss per share (down from JP¥4.69 profit in 2Q 2023). Revenue: JP¥3.10b (flat on 2Q 2023). Net loss: JP¥30.0m (down 138% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Aankondiging • Sep 15
Trans Genic Inc. to Report Q2, 2024 Results on Nov 10, 2023 Trans Genic Inc. announced that they will report Q2, 2024 results on Nov 10, 2023 Reported Earnings • Aug 14
First quarter 2024 earnings released: EPS: JP¥4.63 (vs JP¥1.49 loss in 1Q 2023) First quarter 2024 results: EPS: JP¥4.63 (up from JP¥1.49 loss in 1Q 2023). Revenue: JP¥3.28b (up 33% from 1Q 2023). Net income: JP¥78.0m (up JP¥103.0m from 1Q 2023). Profit margin: 2.4% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 28
Full year 2023 earnings released: JP¥24.28 loss per share (vs JP¥110 profit in FY 2022) Full year 2023 results: JP¥24.28 loss per share (down from JP¥110 profit in FY 2022). Revenue: JP¥11.4b (down 9.1% from FY 2022). Net loss: JP¥409.0m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Aankondiging • Jun 21
Trans Genic Inc. to Report Q1, 2024 Results on Aug 10, 2023 Trans Genic Inc. announced that they will report Q1, 2024 results on Aug 10, 2023 Reported Earnings • May 18
Full year 2023 earnings released: JP¥24.28 loss per share (vs JP¥110 profit in FY 2022) Full year 2023 results: JP¥24.28 loss per share (down from JP¥110 profit in FY 2022). Revenue: JP¥11.4b (down 9.1% from FY 2022). Net loss: JP¥409.0m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥5.00 per share at 0.9% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 26 June 2023. Payout ratio is a comfortable 4.0% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (1.0%). Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: JP¥7.59 (vs JP¥10.54 loss in 3Q 2022) Third quarter 2023 results: EPS: JP¥7.59 (up from JP¥10.54 loss in 3Q 2022). Revenue: JP¥2.92b (flat on 3Q 2022). Net income: JP¥128.0m (up JP¥307.0m from 3Q 2022). Profit margin: 4.4% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Aankondiging • Dec 21
Trans Genic Inc. to Report Q3, 2023 Results on Feb 10, 2023 Trans Genic Inc. announced that they will report Q3, 2023 results on Feb 10, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: JP¥4.69 (vs JP¥21.50 in 2Q 2022) Second quarter 2023 results: EPS: JP¥4.69 (down from JP¥21.50 in 2Q 2022). Revenue: JP¥3.07b (down 9.4% from 2Q 2022). Net income: JP¥79.0m (down 79% from 2Q 2022). Profit margin: 2.6% (down from 11% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director Hotaka Saito was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: JP¥4.69 (vs JP¥21.50 in 2Q 2022) Second quarter 2023 results: EPS: JP¥4.69 (down from JP¥21.50 in 2Q 2022). Revenue: JP¥3.07b (down 9.4% from 2Q 2022). Net income: JP¥79.0m (down 79% from 2Q 2022). Profit margin: 2.6% (down from 11% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Aankondiging • Sep 02
Trans Genic Inc. to Report Q2, 2023 Results on Nov 11, 2022 Trans Genic Inc. announced that they will report Q2, 2023 results on Nov 11, 2022 Reported Earnings • Aug 14
First quarter 2023 earnings released: JP¥1.49 loss per share (vs JP¥35.01 profit in 1Q 2022) First quarter 2023 results: JP¥1.49 loss per share (down from JP¥35.01 profit in 1Q 2022). Revenue: JP¥2.47b (down 25% from 1Q 2022). Net loss: JP¥25.0m (down 104% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Aankondiging • Jun 23
Trans Genic Inc. to Report Q1, 2023 Results on Aug 12, 2022 Trans Genic Inc. announced that they will report Q1, 2023 results on Aug 12, 2022 Reported Earnings • May 16
Full year 2022 earnings released: EPS: JP¥110 (vs JP¥31.44 in FY 2021) Full year 2022 results: EPS: JP¥110 (up from JP¥31.44 in FY 2021). Revenue: JP¥12.6b (up 14% from FY 2021). Net income: JP¥1.88b (up 244% from FY 2021). Profit margin: 15% (up from 4.9% in FY 2021). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Aankondiging • May 15
Trans Genic Inc., Annual General Meeting, Jun 23, 2022 Trans Genic Inc., Annual General Meeting, Jun 23, 2022. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Outside Director Hotaka Saito was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Apr 07
Trans Genic Inc. to Report Fiscal Year 2022 Results on May 13, 2022 Trans Genic Inc. announced that they will report fiscal year 2022 results on May 13, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥3.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 24 June 2022. Payout ratio is a comfortable 5.8% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (3.4%). In line with average of industry peers (0.6%). Reported Earnings • Feb 17
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: JP¥10.54 loss per share (down from JP¥24.36 profit in 3Q 2021). Revenue: JP¥2.94b (down 7.4% from 3Q 2021). Net loss: JP¥179.0m (down 142% from profit in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 16
Second quarter 2022 earnings released: EPS JP¥21.50 (vs JP¥2.02 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥3.39b (up 37% from 2Q 2021). Net income: JP¥373.0m (up JP¥338.0m from 2Q 2021). Profit margin: 11% (up from 1.4% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Aankondiging • Sep 08
Trans Genic Inc. (TSE:2342) entered into share transfer agreement to acquire Lunapas LLC. Trans Genic Inc. (TSE:2342) entered into share transfer agreement to acquire Lunapas LLC on September 7, 2021. As per terms of transaction, Lunapas LLC name will be changed to Lunapas Toxic Pathology Research Institute. March 31, 2021, Lunapas LLC reported Net assets of ¥15.5 million, Total assets of ¥19.736 million, Sales of ¥39.521 million, Operating income of ¥9.258 million and Net income of ¥7.445 million. transaction is expected to complete on November 1, 2021. Acquisition will have a minor impact on the business results for the fiscal year ending March 2022. Valuation Update With 7 Day Price Move • Sep 01
Investor sentiment improved over the past week After last week's 16% share price gain to JP¥611, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 36x in the Biotechs industry in Japan. Total returns to shareholders of 32% over the past three years. Aankondiging • Aug 26
Trans Genic Inc. (TSE:2342) announces an Equity Buyback for 550,000 shares, representing 3.17% for ¥300 million. Trans Genic Inc. (TSE:2342) announces a share repurchase program. Under the program, the company will repurchase up to 550,000 shares, representing 3.17% of its issued share capital for ¥300 million. The purpose of the program is agile capital policy implementation and shareholder return measures in response to changes in the business environment. The program is valid till December 24, 2021. As of August 25, 2021, the company had 17,367,719 shares issued (excluding treasury stock) and 1,422 shares in treasury. Reported Earnings • Jun 29
Full year 2021 earnings released: EPS JP¥31.44 (vs JP¥25.33 loss in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: JP¥11.0b (flat on FY 2020). Net income: JP¥546.0m (up JP¥986.0m from FY 2020). Profit margin: 4.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Reported Earnings • May 17
Full year 2021 earnings released: EPS JP¥31.44 (vs JP¥25.33 loss in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: JP¥11.0b (flat on FY 2020). Net income: JP¥546.0m (up JP¥986.0m from FY 2020). Profit margin: 4.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Reported Earnings • Feb 14
Third quarter 2021 earnings released: EPS JP¥24.36 (vs JP¥1.04 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥3.18b (up 18% from 3Q 2020). Net income: JP¥423.0m (up JP¥405.0m from 3Q 2020). Profit margin: 13% (up from 0.7% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 68% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Jan 19
New 90-day high: JP¥549 The company is up 46% from its price of JP¥377 on 21 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. Is New 90 Day High Low • Dec 24
New 90-day high: JP¥431 The company is up 6.0% from its price of JP¥408 on 25 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period. Aankondiging • Dec 04
Trans Genic Inc. to Report Q3, 2021 Results on Feb 12, 2021 Trans Genic Inc. announced that they will report Q3, 2021 results on Feb 12, 2021 Aankondiging • Sep 03
Trans Genic Inc. to Report Q2, 2021 Results on Nov 12, 2020 Trans Genic Inc. announced that they will report Q2, 2021 results on Nov 12, 2020 
